Kenvue, a producer of Tylenol, will be purchased by Kimberly-Clark for $48 billion

While the Tylenol manufacturer faces White House scrutiny and an unsettling lawsuit, Kimberly-Clark, the maker of Kleenex, announced Monday that it will purchase Kenvue for $48 billion in a historic merger for the consumer sector.

In cash and stock, Kenvue owners will receive $21.01 per share, which is a significant 46.2% premium over the stock’s most recent closing price. Pre-market trading saw a roughly 20% increase in Kenvue shares and a nearly 15% decline in Kimberly-Clark shares.

Robert F. Kennedy Jr.

While acknowledging that there was no proof Tylenol caused autism, United President Robert F. Kennedy Jr. reaffirmed his belief that the evidence of a connection between the two was «highly suggestive.»

Investor sentiment is being adversely affected by lawsuits against Kenvue concerning allegations that its baby powder products caused cancer, in addition to other ongoing actions against Tylenol.

However, Kimberly-Clark anticipates the transaction, which it intends to execute in the second half of 2026, will save roughly $2.1 billion annually.

Through the merger, which is expected to be the biggest acquisition in the U.S. consumer goods industry to date, Kimberly-Clark will have access to Kenvue’s extensive brand portfolio, which includes skin care products like Aveeno and Neutrogena as well as Listerine mouthwash and Band-Aid. It is anticipated that the merged business will bring in about $32 billion a year.

For every Kenvue share that a shareholder owns, they will receive 0.15 Kimberly-Clark shares and $3.50 in cash per share. As calculated by Reuters, this suggests an equity value of $40.32 billion.

A document submitted to authorities states that if the deal fails, either party may have to pay a $1.12 billion cash termination fee.

Following the transaction, Mike Hsu, the CEO of Kimberly-Clark, will take over as both the merged company’s president and CEO.

Kimberly-Clark declared that it has secured committed funding from JPMorgan Chase Bank and intends to use a mix of debt and cash to fund the purchase of Kenvue.For every Kenvue share that a shareholder owns, they will receive 0.15 Kimberly-Clark shares and $3.50 in cash per share. As calculated by Reuters, this suggests an equity value of $40.32 billion.

A document submitted to authorities states that if the deal fails, either party may have to pay a $1.12 billion cash termination fee.

Following the transaction, Mike Hsu, the CEO of Kimberly-Clark, will take over as both the merged company’s president and CEO.

Kimberly-Clark declared that it has secured committed funding from JPMorgan Chase Bank and intends to use a mix of debt and cash to fund the purchase of Kenvue.